Key result
Long-term Class Ic antiarrhythmics show clinical efficacy in ~52% of AF patients despite frequent proarrhythmic discontinuation.
Why the study?
Data on the long-term clinical efficacy and safety of flecainide and propafenone for rhythm control in atrial fibrillation in a real-world setting are scarce.
Does long-term therapy with flecainide or propafenone improve arrhythmia-related symptoms in patients with atrial fibrillation?
Observational (n=361)
No
Does long-term therapy with flecainide or propafenone improve arrhythmia-related symptoms in patients with atrial fibrillation?
Long-term Class Ic antiarrhythmic therapy provides symptom improvement in about half of AF patients but is limited by a high rate of adverse events, particularly proarrhythmia, necessitating careful patient selection.
Answers are grounded in this paper and cite their sources.
Modest long-term symptom control with frequent proarrhythmic discontinuations supports cautious use and close surveillance in selected AF patients; leaves open need for prospective comparative trials.
BACKGROUND: Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF). However, data on long-term clinical efficacy and safety of these drugs in a real-world setting are scarce. METHODS: Patients with AF who received chronic flecainide or propafenone therapy were retrospectively studied from the database of a tertiary care center. The primary outcome of the study was clinical efficacy of Class Ic antiarrhythmics, which was assessed based on the improvement of arrhythmia-related symptoms at the time of last follow-up. RESULTS: Among the 361 patients (261 males, 72.3%) with a mean age of 56 ± 12 years, 287 (79.5%) were using long-term flecainide, and 74 (20.5%) patients propafenone. The majority of the patients had paroxysmal AF (n = 331, 91.7%) and had an atrioventricular-nodal blocking co-medication (n = 287, 79.5%). A total of 117 (32%) patients discontinued therapy after a median of 210 days (interquartile range 62-855 days). Clinical efficacy was observed in 188 (52%) patients. The most common reason for therapy discontinuation was adverse drug effects, particularly proarrhythmic effects (48% for flecainide and 33% for propafenone). Patients who did not clinically benefit from Class Ic antiarrhythmics more often underwent pulmonary vein isolation (p = 0.02). CONCLUSIONS: Long-term therapy with Class Ic antiarrhythmics showed clinical efficacy in approximately half of the patients with paroxysmal or persistent AF. However, these drugs were also associated with a relatively high rate of adverse events, and in particular proarrhythmic effects, which often resulted in therapy discontinuation rendering appropriate patient selection and therapy surveillance essential.
No takes yet. Share an insight, caveat, or question.
Kovacs et al. (2022) conducted an observational in Atrial fibrillation (n=361). Class Ic antiarrhythmics (flecainide or propafenone) was evaluated on Clinical efficacy (improvement of arrhythmia-related symptoms at last follow-up). Long-term therapy with Class Ic antiarrhythmics showed clinical efficacy in 52.1% of patients with atrial fibrillation, though 32% discontinued therapy primarily due to adverse proarrhythmic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: